Progression of mild cognitive impairment to Alzheimer's disease: improved diagnostic value of the combined use of N200 latency and beta-amyloid(1-42) levels

Dement Geriatr Cogn Disord. 2009;28(1):30-5. doi: 10.1159/000229023. Epub 2009 Jul 23.

Abstract

Background/aims: The aim of this study was to investigate the role of cerebrospinal fluid beta-amyloid(1-42) levels and auditory event-related potentials (AERPs) in the progress of mild cognitive impairment (MCI) to Alzheimer's disease (AD).

Methods: In 53 MCI patients, lumbar puncture was performed and beta-amyloid(1-42) levels were determined. Twenty patients were reexamined after 11 months. During this period, 5 of them progressed to AD. Neuropsychological and ERP analyses were performed on all patients during both baseline and endpoint examinations.

Results: Compared to stable MCI patients, those that progressed to AD had significantly lower beta-amyloid(1-42) levels (Mann-Whitney test, Z = -2.952, p = 0.003; effect size r = -0.41) and significantly prolonged N200 latencies (Mann-Whitney test, Z = -3.561, p < 0.001, effect size r = -0.49). From ERP variables, only the N200 latency significantly correlated with beta-amyloid(1-42) levels (baseline examination: r(s) = -0.421, p = 0.002; follow-up examination: r(s) = -0.574, p = 0.008).

Conclusions: The combined use of these two parameters enabled discrimination of stable MCI patients from those who developed AD, with 100% sensitivity and specificity. Therefore, this method could be of high diagnostic value for the early diagnosis of AD.

MeSH terms

  • Aged
  • Alzheimer Disease / blood
  • Alzheimer Disease / diagnosis*
  • Alzheimer Disease / psychology*
  • Amyloid beta-Peptides / cerebrospinal fluid*
  • Biomarkers
  • Cognition Disorders / blood
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / psychology*
  • Discrimination, Psychological / physiology
  • Disease Progression
  • Electroencephalography*
  • Evoked Potentials, Auditory / physiology
  • Female
  • Humans
  • Male
  • Neuropsychological Tests
  • Peptide Fragments / cerebrospinal fluid*

Substances

  • Amyloid beta-Peptides
  • Biomarkers
  • Peptide Fragments
  • amyloid beta-protein (1-42)